Clinical Trials Browser

Completed × AZD 6244 × 30 days × Clear all

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2 Completed

21 enrolled 12 charts

Neurofibromatosis 1, Neurofibrosarcoma